Seqirus to build new U.K. manufacturing outpost

Seqirus--the world's second largest flu vaccine player formed from CSL's purchase of Novartis' ($NVS) flu vaccines--is expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there. The company is the second largest flu vaccine player, behind Sanofi ($SNY), with more than 2,000 employees worldwide. More from FiercePharmaManufacturing

Suggested Articles

Dr. Anthony Fauci will oversee most of the ongoing COVID-19 vaccine trials in the U.S., save for Pfizer's, ProPublica reports.

COVID vaccine and drug trial pauses show that the system is working as intended to verify safety and efficacy, the FDA commissioner told Bloomberg. 

COVID-19 vaccine manufacturing partner Emergent BioSolutions should be protected from financial fallout should J&J's product fail, analysts said.